Selection bias in the use of thrombolytic therapy in acute myocardial infarction

Marc A. Pfeffer, Lemuel A. Moyé, Eugene Braunwald, Lofty Basta, Edward J. Brown, Thomas E. Cuddy, Gilles R. Dagenais, Gregory C. Flaker, Edward M. Geltman, Bernard J. Gersh, Steven Goldman, Gervasio A. Lamas, Milton Packer, Jean L. Rouleau, John D. Rutherford, Richard M. Steingart, John H. Wertheimer

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Objective. - To determine whether clinical selection for thrombolytic therapy for acute myocardial infarction results in a skewed population for subsequent adverse cardiovascular events. Design. - A comparison of the clinical features of the patients in the Survival and Ventricular Enlargement Study who either had or had not received thrombolytic therapy was conducted in both univariate and multiple logistic regression analyses. Setting. - Hospitalized patients experiencing acute myocardial infarction from 112 broadly representative, private, academic, and government hospitals in the United States and Canada. Patients. - All patients in the Survival and Ventricular Enlargement Study had had a recent myocardial infarction (<16 days) and had a left ventricular ejection fraction of 40% or less. Intervention. - Thrombolytic therapy was administered to 733 patients and was not given to 1498. Main Outcome Measures. - The comparisons with respect to use of thrombolytic therapy were formulated after the completion of enrollment and indicated that the majority of patients did not receive thrombolytic therapy. Results. - The 1498 (67.1%) patients who did not receive thrombolytic therapy were at higher risk (older age, lower functional capacity, greater likelihood of a history of prior myocardial infarction, angina, diabetes, and hypertension) for subsequent cardiovascular events and, as anticipated, were more likely to have concomitant gastrointestinal and neurological diseases. A multiple logistic regression analysis indicated that older age, prior myocardial infarction, impaired functional status, employment status, diabetes, and neurological diseases were predictors of use of thrombolytic therapy. Conclusion. - Although the Survival and Ventricular Enlargement Study pop-ulation was selected for left ventricular dysfunction, the majority of patients who currently are judged clinically as unsuitable for thrombolytic therapy have a higher risk for adverse cardiovascular events.

Original languageEnglish (US)
Pages (from-to)528-532
Number of pages5
JournalJournal of the American Medical Association
Volume266
Issue number4
StatePublished - Jul 24 1991
Externally publishedYes

Fingerprint

Selection Bias
Thrombolytic Therapy
Myocardial Infarction
Survival
Logistic Models
Regression Analysis
Gastrointestinal Diseases
Left Ventricular Dysfunction
Stroke Volume
Canada
Outcome Assessment (Health Care)
Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pfeffer, M. A., Moyé, L. A., Braunwald, E., Basta, L., Brown, E. J., Cuddy, T. E., ... Wertheimer, J. H. (1991). Selection bias in the use of thrombolytic therapy in acute myocardial infarction. Journal of the American Medical Association, 266(4), 528-532.

Selection bias in the use of thrombolytic therapy in acute myocardial infarction. / Pfeffer, Marc A.; Moyé, Lemuel A.; Braunwald, Eugene; Basta, Lofty; Brown, Edward J.; Cuddy, Thomas E.; Dagenais, Gilles R.; Flaker, Gregory C.; Geltman, Edward M.; Gersh, Bernard J.; Goldman, Steven; Lamas, Gervasio A.; Packer, Milton; Rouleau, Jean L.; Rutherford, John D.; Steingart, Richard M.; Wertheimer, John H.

In: Journal of the American Medical Association, Vol. 266, No. 4, 24.07.1991, p. 528-532.

Research output: Contribution to journalArticle

Pfeffer, MA, Moyé, LA, Braunwald, E, Basta, L, Brown, EJ, Cuddy, TE, Dagenais, GR, Flaker, GC, Geltman, EM, Gersh, BJ, Goldman, S, Lamas, GA, Packer, M, Rouleau, JL, Rutherford, JD, Steingart, RM & Wertheimer, JH 1991, 'Selection bias in the use of thrombolytic therapy in acute myocardial infarction', Journal of the American Medical Association, vol. 266, no. 4, pp. 528-532.
Pfeffer MA, Moyé LA, Braunwald E, Basta L, Brown EJ, Cuddy TE et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. Journal of the American Medical Association. 1991 Jul 24;266(4):528-532.
Pfeffer, Marc A. ; Moyé, Lemuel A. ; Braunwald, Eugene ; Basta, Lofty ; Brown, Edward J. ; Cuddy, Thomas E. ; Dagenais, Gilles R. ; Flaker, Gregory C. ; Geltman, Edward M. ; Gersh, Bernard J. ; Goldman, Steven ; Lamas, Gervasio A. ; Packer, Milton ; Rouleau, Jean L. ; Rutherford, John D. ; Steingart, Richard M. ; Wertheimer, John H. / Selection bias in the use of thrombolytic therapy in acute myocardial infarction. In: Journal of the American Medical Association. 1991 ; Vol. 266, No. 4. pp. 528-532.
@article{ee9856a2fe784c9684462712ff6c7955,
title = "Selection bias in the use of thrombolytic therapy in acute myocardial infarction",
abstract = "Objective. - To determine whether clinical selection for thrombolytic therapy for acute myocardial infarction results in a skewed population for subsequent adverse cardiovascular events. Design. - A comparison of the clinical features of the patients in the Survival and Ventricular Enlargement Study who either had or had not received thrombolytic therapy was conducted in both univariate and multiple logistic regression analyses. Setting. - Hospitalized patients experiencing acute myocardial infarction from 112 broadly representative, private, academic, and government hospitals in the United States and Canada. Patients. - All patients in the Survival and Ventricular Enlargement Study had had a recent myocardial infarction (<16 days) and had a left ventricular ejection fraction of 40{\%} or less. Intervention. - Thrombolytic therapy was administered to 733 patients and was not given to 1498. Main Outcome Measures. - The comparisons with respect to use of thrombolytic therapy were formulated after the completion of enrollment and indicated that the majority of patients did not receive thrombolytic therapy. Results. - The 1498 (67.1{\%}) patients who did not receive thrombolytic therapy were at higher risk (older age, lower functional capacity, greater likelihood of a history of prior myocardial infarction, angina, diabetes, and hypertension) for subsequent cardiovascular events and, as anticipated, were more likely to have concomitant gastrointestinal and neurological diseases. A multiple logistic regression analysis indicated that older age, prior myocardial infarction, impaired functional status, employment status, diabetes, and neurological diseases were predictors of use of thrombolytic therapy. Conclusion. - Although the Survival and Ventricular Enlargement Study pop-ulation was selected for left ventricular dysfunction, the majority of patients who currently are judged clinically as unsuitable for thrombolytic therapy have a higher risk for adverse cardiovascular events.",
author = "Pfeffer, {Marc A.} and Moy{\'e}, {Lemuel A.} and Eugene Braunwald and Lofty Basta and Brown, {Edward J.} and Cuddy, {Thomas E.} and Dagenais, {Gilles R.} and Flaker, {Gregory C.} and Geltman, {Edward M.} and Gersh, {Bernard J.} and Steven Goldman and Lamas, {Gervasio A.} and Milton Packer and Rouleau, {Jean L.} and Rutherford, {John D.} and Steingart, {Richard M.} and Wertheimer, {John H.}",
year = "1991",
month = "7",
day = "24",
language = "English (US)",
volume = "266",
pages = "528--532",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Selection bias in the use of thrombolytic therapy in acute myocardial infarction

AU - Pfeffer, Marc A.

AU - Moyé, Lemuel A.

AU - Braunwald, Eugene

AU - Basta, Lofty

AU - Brown, Edward J.

AU - Cuddy, Thomas E.

AU - Dagenais, Gilles R.

AU - Flaker, Gregory C.

AU - Geltman, Edward M.

AU - Gersh, Bernard J.

AU - Goldman, Steven

AU - Lamas, Gervasio A.

AU - Packer, Milton

AU - Rouleau, Jean L.

AU - Rutherford, John D.

AU - Steingart, Richard M.

AU - Wertheimer, John H.

PY - 1991/7/24

Y1 - 1991/7/24

N2 - Objective. - To determine whether clinical selection for thrombolytic therapy for acute myocardial infarction results in a skewed population for subsequent adverse cardiovascular events. Design. - A comparison of the clinical features of the patients in the Survival and Ventricular Enlargement Study who either had or had not received thrombolytic therapy was conducted in both univariate and multiple logistic regression analyses. Setting. - Hospitalized patients experiencing acute myocardial infarction from 112 broadly representative, private, academic, and government hospitals in the United States and Canada. Patients. - All patients in the Survival and Ventricular Enlargement Study had had a recent myocardial infarction (<16 days) and had a left ventricular ejection fraction of 40% or less. Intervention. - Thrombolytic therapy was administered to 733 patients and was not given to 1498. Main Outcome Measures. - The comparisons with respect to use of thrombolytic therapy were formulated after the completion of enrollment and indicated that the majority of patients did not receive thrombolytic therapy. Results. - The 1498 (67.1%) patients who did not receive thrombolytic therapy were at higher risk (older age, lower functional capacity, greater likelihood of a history of prior myocardial infarction, angina, diabetes, and hypertension) for subsequent cardiovascular events and, as anticipated, were more likely to have concomitant gastrointestinal and neurological diseases. A multiple logistic regression analysis indicated that older age, prior myocardial infarction, impaired functional status, employment status, diabetes, and neurological diseases were predictors of use of thrombolytic therapy. Conclusion. - Although the Survival and Ventricular Enlargement Study pop-ulation was selected for left ventricular dysfunction, the majority of patients who currently are judged clinically as unsuitable for thrombolytic therapy have a higher risk for adverse cardiovascular events.

AB - Objective. - To determine whether clinical selection for thrombolytic therapy for acute myocardial infarction results in a skewed population for subsequent adverse cardiovascular events. Design. - A comparison of the clinical features of the patients in the Survival and Ventricular Enlargement Study who either had or had not received thrombolytic therapy was conducted in both univariate and multiple logistic regression analyses. Setting. - Hospitalized patients experiencing acute myocardial infarction from 112 broadly representative, private, academic, and government hospitals in the United States and Canada. Patients. - All patients in the Survival and Ventricular Enlargement Study had had a recent myocardial infarction (<16 days) and had a left ventricular ejection fraction of 40% or less. Intervention. - Thrombolytic therapy was administered to 733 patients and was not given to 1498. Main Outcome Measures. - The comparisons with respect to use of thrombolytic therapy were formulated after the completion of enrollment and indicated that the majority of patients did not receive thrombolytic therapy. Results. - The 1498 (67.1%) patients who did not receive thrombolytic therapy were at higher risk (older age, lower functional capacity, greater likelihood of a history of prior myocardial infarction, angina, diabetes, and hypertension) for subsequent cardiovascular events and, as anticipated, were more likely to have concomitant gastrointestinal and neurological diseases. A multiple logistic regression analysis indicated that older age, prior myocardial infarction, impaired functional status, employment status, diabetes, and neurological diseases were predictors of use of thrombolytic therapy. Conclusion. - Although the Survival and Ventricular Enlargement Study pop-ulation was selected for left ventricular dysfunction, the majority of patients who currently are judged clinically as unsuitable for thrombolytic therapy have a higher risk for adverse cardiovascular events.

UR - http://www.scopus.com/inward/record.url?scp=0025769831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025769831&partnerID=8YFLogxK

M3 - Article

C2 - 2061979

AN - SCOPUS:0025769831

VL - 266

SP - 528

EP - 532

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 4

ER -